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Abstract
Flavonoids, both naturally occurring and synthetic, are known to have multiple effects on 
the activation of ionotropic receptors for γ-aminobutyric acid (GABA), the major inhibi-
tory neurotransmitter in our brains. They can act as positive or negative allosteric modu-
lators, enhancing or reducing the effect of GABA. They can elicit a direct activation of 
the receptors. They can also act to modulate the action of other modulators. This ability 
to influence function via their actions on GABA receptors permits a range of effects of 
flavonoids, including relief of anxiety, anticonvulsant, analgesic and sedative actions.
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1. Introduction
Flavonoids have shown a range of effects, such as anxiolytic, sedative, anticonvulsant and 
analgesic properties, via their actions on the central nervous system (CNS). These effects occur 
through a variety of interactions with different receptors and signalling systems, including 
γ-aminobutyric acid (GABA) receptors. γ-Aminobutyric acid (GABA) is the primary inhibi-
tory neurotransmitter in the mammalian brain, released by up to 40% of neurons [1]. GABA 
acts on two classes of receptors—ionotropic and metabotropic [2]. Ionotropic receptors for 
GABA are ligand-gated chloride channels located in the neuronal membrane. When activated 
by GABA, these channels permit the passage of chloride ions down their electrochemical 
gradient. This usually results in the inward flow of chloride ions and the inhibition of neuro-
nal firing. Metabotropic receptors for GABA are G-protein-coupled receptors that modulate 
neuronal activity via a variety of second messengers. While an extensive literature on the 
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interactions of flavonoids with ionotropic GABA receptors exists [3], there are no examples 
of flavonoids acting on metabotropic GABA receptors, though they are known to act on other 
G-protein-coupled receptors such as adrenergic receptors [4].
This overview highlights the effects of some representative flavonoids on ionotropic GABA 
receptors acting as positive or negative allosteric modulators, increasing or decreasing the 
effect of GABA, as directly acting allosteric agonists, and as second-order modulators influ-
encing the action of other modulators. Of particular interest are flavonoids that show subtype 
selectivity on GABA receptors. This overview also highlights the pre-clinical evidence for these 
representative flavonoids as anxiolytics, sedatives and anticonvulsants through their interac-
tions with the GABAergic system. Further, the synergistic actions of flavonoids are reviewed.
2. Ionotropic GABA receptors
There are two classes of ionotropic GABA receptors: GABAA and GABAC receptors. GABAA receptors are relatively complex proteins, while GABAC receptors are relatively simple [2]. These receptors are pharmacologically distinguished by selective antagonists—GABAA 
receptors are antagonized by the convulsant alkaloid bicuculline and are insensitive to 
(1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid (TPMPA), whereas GABAC receptors are insensitive to bicuculline and are selectively antagonized by TPMPA. GABAB receptors are metabotropic receptors selectively activated by the GABA analogue baclofen, and insensi-
tive to bicuculline and TPMPA. GABAA, GABAB and GABAC receptors differ in their physiol-ogy, pharmacology and molecular biology.
Ionotropic GABA receptors are part of a superfamily of ligand-gated ion channels comprising 
excitatory, cation-selective channels such as nicotinic acetylcholine receptors, 5-HT
3
 receptors 
and zinc-activated channels, as well as inhibitory, anion-selective channels such as GABAA and GABAC receptors, strychnine-sensitive glycine receptors and invertebrate glutamate-gated chloride channels [5]. Receptors of this superfamily require five subunits to assemble 
a single ion channel. The ion channel may be homomeric formed by five identical subunits 
as is the case of GABAC receptors, or heteromeric, consisting of a combination of at least two different subunits, for example, the GABAA receptors [6]. This superfamily of ligand-gated ion channels is referred to as the cys-loop receptors due to a conserved characteristic cys-cys 
disulphide bond forming a loop of 13 amino acids in the N-terminal extracellular domain that 
contains the orthosteric agonist-binding site for the transmitter. The cys-loop is believed to be 
important for both cell surface expression of the receptor and cooperative interaction between 
agonist-binding sites and the channel gate.
GABAA receptors are heteromeric pentamers, composed of a variety of protein subunits. In humans, there are 19 isoforms of GABAA subunits, that is, six α, three β, three γ and one of δ, ε, π, θ, known to form heteromeric GABAA receptors. The most widely distributed complex in the brain is composed of two α, two β and one γ subunit, but many other combinations are 
known to be found in specific brain areas. Theoretically, many thousands of GABAA  receptors 
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could exist, made up of different combinations of subunits. Specific subunit combinations 
are thought to be associated with selective actions [7]. Using transgenic mice, it was demon-
strated that receptors containing α1-subunits serve as targets for sedative-hypnotics-mediat-
ing sedation, while α2- and/or α3-containing receptors mediate anxiolysis, and α5-containing 
receptors are involved in memory [8].
The action of GABA on GABAA receptors can be modulated by many well-known agents. These include benzodiazepines, such as diazepam, barbiturates, anaesthetic agents, ethanol, 
neurosteroids and flavonoids. Consequently, modulators of GABAA receptors are important targets for drug development, particularly modulators that are selective for GABAA receptors made up of specific subunit combinations [7].
GABAC receptors are relatively simple compared to GABAA receptors. Three subunits, ρ1, ρ2 and ρ3, have been cloned from retina and restricted brain regions [9]. These subunits usually 
express as pentameric homomeric GABAC receptors that are activated by lower concentra-tions of GABA than GABAA receptors. The amino acid sequence similarity between GABAA and GABAC subunits is 35–45% and is as high as 75% in the transmembrane region. The genes coding for the three GABAC subunits are found on different chromosomes to those coding for GABAA subunits. Modulators of GABAC receptors are rare (zinc, lanthanides and some neurosteroids), although some flavonoids have been show to inhibit GABAC receptors, for example, apigenin and quercetin [10, 11]. GABAA and GABAC receptors have distinct phar-macological profiles, with some agents having opposite effects (agonist/antagonist) on the 
two classes of receptors. As GABAC receptors are much less widely distributed in the brain than GABAA receptors, they are considered to be important targets for drug development [9].
2.1. Flavonoids and benzodiazepines
Flavonoids were first linked to benzodiazepines when S-(−)-equol, 4′-hydroxy-7-methoxyi-
soflavone and 3′,7-dihydroxyisoflavone, isolated from bovine urine, were shown to inhibit 
benzodiazepine binding to brain membranes [12]. These flavonoids most likely originated 
from plant sources in the bovine diet. The pioneering studies on naturally occurring and syn-
thetic flavonoids carried out by the research groups of Marder, Medina, Paladini in Argentina 
during the 1990s drew attention to flavonoids as initially as ‘a new family of benzodiazepine 
receptor ligands [13, 14].
At the time of initial research into flavonoids at GABA receptors, benzodiazepines were 
amongst the most widely prescribed pharmaceuticals, and numerous flavonoids of the vari-
ous classes were investigated both in vitro and in vivo as potential leads for novel benzodiaz-
epine site ligands. The major therapeutic actions of benzodiazepines are now known to result 
from their action as positive allosteric modulators of GABA at GABAA receptors, that is, they enhance the action of GABA on these receptors by acting at another site on GABAA receptors distinct from site that interacts with GABA. This positive modulatory action of benzodiaz-
epines can be antagonized by flumazenil, a neutralizing modulator used therapeutically to 
reverse benzodiazepine effects. Benzodiazepines have also been shown to act at high concen-
trations via a flumazenil-insensitive low-affinity-binding site, separate to the high-affinity, 
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flumazenil-sensitive-binding site [15]. Thus, benzodiazepines act via ‘two distinct and sepa-
rable mechanisms’ on GABAA receptors.
Flavonoids have been shown to modulate GABAA receptors at low concentrations in either a flumazenil-sensitive or flumazenil-insensitive manner [3]. Thus, flavonoids can influence 
GABAA receptors via the classical benzodiazepine-binding site, as well as independently of the classical benzodiazepine-binding site [3, 16]. Many flavonoids elicit biphasic responses, 
enhancing GABA actions at low concentrations and inhibiting at high concentrations. 
Additionally, some flavonoids act as agonists particularly at high concentrations and directly 
gate the receptor in the absence of GABA [17]. Clearly then, flavonoids interact with at least 
two, and possibly more specific active sites on GABAA receptors.
2.2. Types of flavonoids
Flavonoids form a class of molecules that consist of a benzopyran moiety (A and C rings) with 
a phenyl substituent (B ring), as shown in Figure 1. The degree of oxidation of the C ring, the 
hydroxylation pattern of the C ring structure and the substitution in the 3-position demarcate 
the different subgroups of flavonoids [18]. The predominant subgroups of naturally occurring 
flavonoids include flavonols (e.g. quercetin [10]), flavones (e.g. apigenin and luteolin [19, 20]), 
isoflavones (e.g. genistein [21]), flavanones (e.g. naringenin [22]) and flavanols (e.g. epigal-
locatechin gallate (EGCG) [11]). Each of the flavonoids listed is known to influence GABAA receptors and to produce CNS effects.
2.3. Apigenin, hispidulin and luteolin
The flavones apigenin, hispidulin and luteolin are closely related structurally, as shown in 
Figure 2. Compared with apigenin, hispidulin has an extra methoxy group in the 6-position 
and luteolin has an extra hydroxyl group in the 4′-position (Figure 2). These small structural 
differences significantly impact the effects of these flavones on experimental animal behav-
iours and on GABAA receptors.
Figure 1. Structure of flavone, showing the generic structure of flavonoids with numbering system and ring designation.
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Apigenin (Figure 2), the major flavonoid found in chamomile (Matricaria chamomilla), has 
complex modulatory actions on GABAA receptors. In cultured cerebellar granule cells, api-genin is described as a negative modulator of GABA action, and it is a weak inhibitor of 
flumazenil binding to cerebellar membranes [19]. The inhibition of the GABA response at 
α1β2γ2S GABAA receptors expressed in oocytes in the presence of flumazenil (0.1–1 mM) was the first definitive report of the flumazenil-insensitive actions of flavonoids on recombinant 
GABAA receptors [10]. Similar flumazenil-insensitive negative modulatory actions of apigenin on recombinant GABAA receptors were subsequently reported by other investigators [11, 23].
Functional electrophysiological studies have also demonstrated that apigenin can act as a 
second-order modulator of the first-order modulation of GABAA receptors by benzodiaze-pines [11]. This effect of apigenin was observed at concentrations where apigenin alone had 
no detectable modulatory effects on GABA responses. The second-order positive modulation 
of the diazepam-enhanced response was observed at the maximal flumazenil-sensitive con-
centration of diazepam. It is unlikely that apigenin acts by enhancing diazepam binding as 
it is known to inhibit such binding. Furthermore, apigenin does not influence the binding of 
Figure 2. Structures of the flavanones apigenin, hispidulin and luteolin with the differences from apigenin circled.
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muscimol, a potent GABAA agonist. The observed second-order modulation may result from alterations in the coupling of the flumazenil-sensitive benzodiazepine allosteric sites with the 
orthosteric GABA sites on GABAA receptors. This action was selective for diazepam modula-tion and was not observed for pentobarbitone or allopregnanolone enhancement. In order for 
this to be a mechanism for the inhibition of locomotor activity by apigenin, there would have 
to be primary modulation by endogenous benzodiazepines, the so-called endozepines [24].
The second-order modulation (or metamodulation) has also been noted in other systems [25, 
26] and may represent an obscure novel mechanism of drug action deserving further inves-
tigation, with the potential to lead to decreased therapeutic doses. It is not easy to study as 
it involves the dose-dependent interactions between three ligands, requiring the study of a 
number of dose combinations, and thus may be difficult to observe. Synergistic interactions 
have been described between other flavonoids on GABA receptor-related behaviours [27–29] 
and at glycine receptors between strychnine and flavonoids [30]. Complex tertiary interac-
tions between flavonoids and other substances may be a subtle feature of cys-loop ligand-
gated ion channels.
Clear anxiolytic effects for apigenin have been shown using the elevated plus maze model 
of anxiety in mice at doses that did not cause myorelaxation or sedation [29, 31], and in rats 
(5 mg/kg) [32], as did apigenin 7-glucoside (2.5 and 5 mg/kg) [32]. One study using rats was 
unable to demonstrate an anxiolytic effect of apigenin on the light-dark avoidance model 
of anxiety at doses of 1–25 mg/kg [33]. On the other hand, 25 mg/kg apigenin was shown to 
inhibit locomotor activity in a flumazenil-insensitive manner, since flumazenil pre-treatment 
did not inhibit this effect [33]. It was concluded that the sedative action of apigenin seen in 
this study ‘cannot be ascribed to an interaction with GABA-benzodiazepine receptor, since 
it is not counteracted by the benzodiazepine antagonist flumazenil’ [33]. Nevertheless, this 
study was undertaken prior to the discovery of the flumazenil-insensitive action of flavonoids 
on GABAA receptors. Other possible mechanisms for the action of apigenin on locomotor 
activity include reduced activation by l-glutamate of NMDA receptors [34] and inhibition of 
l-glutamate release via reduction of calcium ion entry [35].
The strongest evidence for flavonoid modulation of GABAA receptors in the brain comes from the anticonvulsant hispidulin, found in the sage plant (Salvia officinalis) (Figure 2) [36]. 
Structurally, hispidulin differs from apigenin only by the addition of a 6-methoxy substituent. 
In functional studies on recombinant α1β2γ2 GABAA receptors expressed in Xenopus oocytes, hispidulin was inactive when applied alone, and at concentrations up to 10 μM was found 
to positively modulate the effect of 4 μM GABA [23]. This positive modulation was partially 
blocked by flumazenil. However, hispidulin at 10 μM was inactive at α1β2 receptors, which 
lack the flumazenil-sensitive benzodiazepine site. Hispidulin was further shown to exhibit 
a biphasic action and to be approximately equipotent at each of six different α-subunit con-
taining GABAA receptors—α1,2,3,5,6β2γ2S, enhancing at low concentrations (EC50 0.8–5 mM) and inhibiting at higher concentrations (>30 mM). The fact that hispidulin is inactive at α
1
β
2
 
receptors but is active at α6-containing receptors that are insensitive to benzodiazepines sug-
gests that hispidulin may act via more than one binding site on GABAA receptors, at least one of which may represent a novel site. Interestingly, previous studies indicated that a range of 
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natural and synthetic flavones had no affinity for recombinant α6β3γ receptors [37]. Thus, 
hispidulin appears to show a different profile of activity to apigenin at GABAA receptor subtypes.
Hispidulin was also shown to displace 3H-flumazenil binding in human frontal cortex crude 
synaptic membrane preparations [38]. Using 14C-hispidulin, the flavone was found to pass the 
blood-brain barrier using a rat perfusion model [23]. Further, hispidulin exhibited a flumaze-
nil-sensitive anticonvulsant action, similar to diazepam, in seizure-prone Mongolian gerbils 
used as an animal model of epilepsy [23].
Luteolin (Figure 2), found in many plants including celery and green pepper, differs from api-
genin by an additional 3′-hydroxyl group. Following acute administration in mice, luteolin at 
doses of 1–50 mg/kg failed to demonstrate anticonvulsant or myorelaxation effects, or to have 
any impact on locomotor activity [39]. On the other hand, 5 mg/kg luteolin increased open-
arm entries in the elevated plus maze, suggesting an anxiolytic effect, and reduced haloperi-
dol-induced catalepsy [39]. Both of these effects, however, disappeared at higher doses tested. 
Another study testing 50 mg/kg luteolin in rats in the elevated plus maze also failed to dem-
onstrate any anxiolytic action [40], though this may be partly explained by the finding that 
the same dose reduced locomotor activity, suggesting a sedative effect that may have masked 
any anxiolytic action. Although it has not been tested in vitro, it may also be possible that, like 
some other flavonoids, luteolin possesses positive allosteric modulatory actions at low doses 
and negative allosteric modulation at higher doses. A combination of flumazenil with luteolin 
also failed to show any significant difference to the control group, and the researchers con-
cluded that ‘luteolin does not produce anxiolysis by modulation of the GABAA receptor' [40]. Given that we now know of flumazenil-insensitive actions of flavonoids on GABAA receptors, this may be an incorrect conclusion.
Following chronic administration (14 days), luteolin showed antidepressant activity in the 
forced swim test, significantly reducing latency to immobilization and increasing total immo-
bilization to the same extent as diazepam, interpreted as increased adaptation (rather than 
increased helplessness) in the model used [39]. Further evidence of luteolin’s antidepressant 
activity was shown using the forced swim test [20]. A dose-dependent reduction in the dura-
tion of immobility was observed in mice following acute administration of doses (5 and 10 
mg/kg) that did not alter locomotor activity when tested using the open field.
In a rat neuropathic pain model, luteolin produced analgesia in a bicuculline-sensitive, 
flumazenil-insensitive manner [23]. Luteolin (10 mg/kg) also improved spatial memory in 
rats in a scopolamine-induced amnesia model in the Y maze [41], although the proposed 
mechanisms relate to brain-derived neurotrophic factor, acetylcholine and lipid peroxidation. 
Further studies are required to demonstrate any involvement of the GABAergic system in this 
observed memory enhancement. Finally, a study of luteolin in four mouse seizure models 
showed no anticonvulsant activity [42].
Evidence that some of these behavioural effects of luteolin may be mediated by binding to 
GABAA receptors exists. Luteolin displaced 3H-flunitrazepam (1.5 nM) binding on rat cortical 
crude synaptic membrane preparations, with a K
i
 of 60 μM, suggesting weak binding to the 
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benzodiazepine-binding site on GABAA receptors [39]. Further, luteolin was shown to pro-mote GABA-mediated chloride influx in human neuroblastoma cells, which was attenuated 
by the GABAA receptor antagonist bicuculline [20].
The studies reviewed here reveal that apigenin, hispidulin and luteolin appear to show dif-
fering profiles of activity at GABAA receptor subtypes and differing effects in vivo, demon-strating that small differences in chemical structure have profound effects on the biological 
properties of these flavonoids.
2.4. (−)-Epigallocatechin gallate (EGCG)
EGCG (Figure 3) is a flavanol, and the major polyphenol in green tea (Camellia sinensis) [43]. 
At low concentrations, EGCG (0.1 mM) has a potent second-order modulatory action on the 
first-order modulation by diazepam at α1β2γ2L GABAA receptors but inhibits the action of GABA at higher concentrations (>1 mM) [11]. As a second-order modulator, EGCG is an order 
of magnitude more potent than apigenin [11]. In addition, it has been found that EGCG, at 
concentrations that have no influence on the activation of GABAA receptors by GABA, was able to reverse β-carboline (a negative modulator of GABAA receptors)-mediated inhibition of GABA currents in cultured hippocampal neurons [44]. Also, up to 100 μM EGCG significantly 
increased chloride influx in primary cultured cerebellar cells [45]. This indicates that EGCG 
may act as a second-order modulator with respect to the first-order modulation by both posi-
tive and negative modulators that act via benzodiazepine-binding sites on GABAA receptors.
EGCG demonstrates dose-dependent stress-reducing, anxiolytic, sedative and hypnotic prop-
erties in a number of animal models [44–46], with evidence that these activities are mediated 
at least in part by GABAA receptors [44, 46]. EGCG has effects on learning and memory [47] that may be useful in the treatment of Alzheimer’s disease [48]. It has also been suggested 
for Parkinson’s disease therapy [49] while some novel EGCG derivatives may be useful for 
neuropathic pain [50]. It is possible that activity at GABAA receptors underlies many of the reported actions of EGCG.
2.5. Synthetic flavonoids
Classical structure activity-based design led to the development of synthetic flavonoid 
ligands with high affinity for the classical flumazenil-sensitive benzodiazepine-binding site 
on GABAA receptors [51]. Numerous synthetic flavonoids have been shown to influence GABAA receptors. Of particular interest are a series of 6-substituted flavones that show the full repertoire of effects on GABAA receptors: positive, neutralizing and negative modula-tion and direct activation [3, 52], at both the flumazenil-sensitive benzodiazepine site and 
flumazenil-insensitive site(s).
6-Bromoflavone was shown to be a flumazenil-sensitive positive allosteric modulator at 
GABAA receptors, whereas 6-fluoro- and 6-chloroflavone were demonstrated to act as neutral-izing modulators [52]. On the other hand, 6,2′-dihydroxyflavone was found to be a negative 
modulator. By contrast, 6-methylflavone has been shown to act as a flumazenil-insensitive 
modulator of GABAA receptors [53].
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2′-Methoxy-6-methylflavone has demonstrated anxiolytic effects in mice at 1 and 10 mg/kg 
using the elevated plus maze model of anxiety [54]. It was also found to act as a positive 
modulator at α2β1γ2L and all α1-containing GABAA receptor subtypes, demonstrated via recombinant GABAA receptors expressed in Xenopus oocytes [54]. By contrast, it directly activated α2β2/3γ2L receptors without potentiating GABA [54]. Activation by 2′-methoxy-
6-methylflavone was attenuated by bicuculline and gabazine but not flumazenil, indicating 
Figure 3. Structures of the flavanols EGCG, Fa131 and Fa173.
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a novel site of action. This suggests that there is a further flavonoid site on GABAA receptors that mediate opening of the chloride channel in the absence of GABA.
Quantitative structure-efficacy relationships have shown that flavone analogues differing only 
at position 6 show significantly different pharmacological properties at GABAA receptors [52]. This study clearly shows the importance of the 6-position as a determination of activity. 
However, further studies on 6-substitued flavones are needed to study the complex nature of 
the activation and modulation of GABAA receptor subtypes and to explore the unique thera-peutic potential of these synthetic flavones.
Another interesting series of synthetic flavonoids are the flavan-3-ol esters, analogues of 
EGCG, a naturally occurring flavanol-3-ester. Fa131 (trans-(2S,3R)-3-acetoxy-4′-methoxyflavan, 
Figure 3) is a non-sedating anxiolytic and a selective positive modulator of α2-containing 
GABAA receptors, shown on the basis of efficacy [55, 56]. The efficacy of 2100% enhancement exceeds the highest efficacy previously recorded, which was 1250% by (+)-borneol at these 
receptors [57].
Fa173 (cis-(2S,3S)-3-acetoxy-3′,4′-dimethoxyflavan, Figure 3), a diastereo-isomeric flavan-3-ol 
ester with additional methoxy in the 3′ position, was shown to block the modulatory actions 
of Fa131 [58]. Additionally, Fa173 also blocked the enhancement of the GABA response by 
the anaesthetic etomidate, the sedative anticonvulsant loreclezole, and selectively blocked the 
low-affinity effect of diazepam (100 μM) at α1β2γ2L and α1β2 GABAA receptors, but not the high-affinity effect of diazepam (100 nM). Fa173 was found not to inhibit the positive modu-
lation of GABA by the anaesthetic propofol, barbiturate thiopental, or neuroactive steroid 
allopregnanolone. This suggests that Fa131, etomidate, loreclezole and high (non-flumazenil-
sensitive) doses of benzodiazepine all exert their positive modulatory effects via a common or 
overlapping binding site that can be blocked by the neutralizing modulator Fa173. Of these 
agents, Fa131 alone shows selectivity for α2-containing GABAA recombinant receptors. Fa131 is the first positive modulator to distinguish between α2- and α3-containing GABAA recep-tors, highlighting the potential of targeting flumazenil-insensitive allosteric sites in the search 
for new anxio-selective drugs.
2.6. Synergism between flavonoids
As flavonoids are significant constituents of our diet, it is important that we understand how 
natural flavonoids might influence brain function. Except when consumed as dietary supple-
ments, flavonoids are generally consumed as a mixture of different flavonoids from one or 
more foodstuffs [59]. The effects of mixtures of flavonoids and other modulators on GABAA receptors need to be more thoroughly investigated. Synergies have been noted between indi-
vidual flavonoids [29, 60, 61], and between flavonoids and benzodiazepines [27, 28].
Hesperidin, a glycosylated flavonone isolated from Valerian species, has shown syner-
gistic effects in mice. The combination of hesperidin (2 mg/kg) with apigenin (1 mg/kg), 
6,3′-dinitroflavone (0.02 mg/kg) or diazepam (0.3 mg/kg) enhanced the barbiturate-induced 
sleeping time in mice [27, 29]. Both hesperidin and diazepam administered separately 
showed a dose-dependent reduction in exploratory parameters (number of head dips, 
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time spent head- dipping and rearing behaviour), indicative of increased sedation, in mice 
on the holeboard assay [27]. Isobolar analysis revealed synergism between diazepam and 
hesperidin when administered together. For all exploratory parameters measured, a 1.3 
to 2-fold increase in potency was observed compared to the administration of either drug 
alone. Further, these synergistic actions could not be explained by any influence of either 
drug on plasma concentrations of the other [27]. Loscalzo et al. [28] further demonstrated 
a potentiation of sedation in mice when hesperidin was administered together with either 
bromazepam, alprazolam, flunitrazepam or midazolam, through a reduction in explor-
atory parameters and locomotor activity using the holeboard assay and open-field test, 
respectively.
Using human mammary epithelial carcinoma cells (MCF-7), Choi and colleagues [60] showed 
that isoflavones daidzein (derived from soybean) and baicalein (from Scutellaria baicalensis) 
stimulated oestrogen receptor phosphorylation and transcriptional activation of oestrogen-
responsive element (ERE). When tested together, the observed effects on oestrogen receptor 
phosphorylation and transcription of the ERE were further increased in comparison to when 
the drugs were tested alone. A combination of baicalein and daidzein was shown to produce 
a synergistic effect in stimulating oestrogenic activity in MCF-7 cells, calculated using the 
median-effect principle. Further, using an Aβ-aggregation assay to model cellular pathology 
of Alzheimer’s disease, daidzein and baicalein were demonstrated to reduce Aβ-aggregation. 
As oestrogen is neuroprotective, this synergistic action of the isoflavones on oestrogen recep-
tors, as well as in reducing Aβ-aggregation, suggests that the combination of flavonoids could 
provide valuable neuroprotective effects and prevention of neurodegenerative disease [60].
Another study examining the synergistic effects of flavonoids found that the flavonol EGCG 
and the flavone luteolin synergistically inhibited TGF-β-induced myofibroblast phenotypes in 
prostate fibroblast cell lines [61]. Myofibroblasts are converted from fibroblasts by TGF-β and 
IL-6 in the tumour microenvironment. These cells play a role in cell proliferation, migration 
and invasion. TGF-β-induced fibronectin expression was used as a marker of myofibroblast 
expression. Both EGCG (20–40 μM) and luteolin (20 μM) were shown to reduce TGF-β-
induced fibronectin expression alone. In combination, these compounds showed greater 
efficacy in reducing fibronectin expression at concentrations that were less effective when 
administered alone. The authors concluded that a combination of EGCG and luteolin could 
prove effective in reducing the toxic effects of either compound by requiring lower doses, 
and in preventing advancement of tumour growth by reducing the myofibroblast phenotype.
3. Conclusion
Since flavonoids were first linked to benzodiazepine-binding sites on GABAA receptors many years ago, recent studies have clearly demonstrated that the actions of flavonoids on these 
receptors are far more complex than a single action at a single site. In addition to the now rela-
tively well-characterized flumazenil-sensitive benzodiazepine-binding sites, there is signifi-
cant interest in flumazenil-insensitive, non-benzodiazepine-binding sites for flavonoids. This 
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overview has sought to highlight the action of representative flavonoids on GABAA receptors to illustrate the range of activities.
Recent studies have identified the presence of multiple sites on ionotropic GABA receptors at 
which flavonoids can act, modulating the effect of GABA. The sites may include ones that are 
insensitive to the classical benzodiazepine-binding site antagonist (neutralizing modulator) 
flumazenil and described as low-affinity benzodiazepine sites [15]. Perhaps, these would be 
more appropriately described as flavonoid sites as they appear to be activated by many natu-
rally occurring and synthetic flavonoids.
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